Beijing InnoCare Pharma Tech

CompanyChina

ROR

Beijing InnoCare Pharma Tech develops one asset, in phase 3 (orelabrutinib in diffuse large B-cell lymphoma). Mostly small molecule acting on BTK; based in China.

1
Asset
Furthest stage
Phase 3
15
Trials
5
Signals

Pipeline

1
  • orelabrutinib

    Inhibits Bruton's tyrosine kinase, blocking B-cell receptor signaling and malignant B-cell survival.

    Phase 3, Small molecule, BTK, diffuse large B-cell lymphoma, mantle cell lymphoma

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials16
  • Signals9
  • Similar companies6

Intelligence